Replimune Announces Initiation of the Phase 2 Portion of its Ongoing Phase 1/2 Clinical Trial of RP1 as Monotherapy and in Combination with Nivolumab

NEXT STORY
Celldex Announces Data from CDX-3379 Clinical Program Presented at ASCO 2019; Promising Biomarker Strategy Identified for Head and Neck Squamous Cell Carcinoma
PREV STORY
Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care, supported by Helsinn, awarded to Dr. Allison Barz Leahy, MD, University of Pennsylvania
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

JDRF advocates for all Canadians living with type 1 diabetes to be eligible for the Disability Tax Credit

TORONTO, Oct. 23, 2017 (GLOBE NEWSWIRE) -- JDRF Canada believes that every Canadian with ...

author_avatar
NASDAQ Market News

Celldex Therapeutics Appoints Diane C. Young, M.D. as Senior Vice President, Chief Medical Officer

author_avatar
NASDAQ Market News

Aadi Bioscience Appoints Loretta Itri as Chief Medical Officer

author_avatar
NASDAQ Market News